The latest from TV, Radio, and Newspapers

Add a news source

Are we missing a Brisbane news source? Let us know!

Brisbane Newswire

Comprehensive Real-Time News Feed for Brisbane, CA.

Results 1 - 20 of 56 for "u:americanbankingnews.com" in Brisbane, CA

  1. Equities Research Analysts' Updated EPS Estimates for March,...Read the original story w/Photo

    Monday Mar 20 | AmericanBankingNews.com

    According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage.

    Comment?

  2. Zacks Investment Research Downgrades Aimmune Therapeutics Inc (AIMT) to SellRead the original story w/Photo

    Monday Mar 20 | AmericanBankingNews.com

    According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage.

    Comment?

  3. Research Analysts' Downgrades for January, 17th (AIMT, ALDX, ATSG,...Read the original story w/Photo

    Jan 17, 2017 | AmericanBankingNews.com

    According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage.

    Comment?

  4. Zacks Investment Research Lowers Aimmune Therapeutics, Inc. (AIMT) to HoldRead the original story w/Photo

    Jan 17, 2017 | AmericanBankingNews.com

    According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage.

    Comment?

  5. CareDx, Inc. (CDNA) Downgraded to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Jan 16, 2017 | AmericanBankingNews.com

    According to Zacks, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients.

    Comment?

  6. Atara Biotherapeutics, Inc. (ATRA) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Jan 4, 2017 | AmericanBankingNews.com

    According to Zacks, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.

    Comment?

  7. Research Analysts' Upgrades for January, 4th (ATRA, BANR, BKEP,...Read the original story w/Photo

    Jan 4, 2017 | AmericanBankingNews.com

    According to Zacks, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.

    Comment?

  8. Aimmune Therapeutics, Inc. (AIMT) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Jan 3, 2017 | AmericanBankingNews.com

    The brokerage currently has a $23.00 price objective on the stock. Zacks Investment Research's price objective would suggest a potential upside of 11.76% from the company's previous close.

    Comment?

  9. Investment Analysts' Upgrades for January, 3rd (AIMT, AIQUY, AIRM,...Read the original story w/Photo

    Jan 3, 2017 | AmericanBankingNews.com

    They currently have $23.00 price target on the stock. According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies.

    Comment?

  10. Stock Analysts' Updated EPS Estimates for November, 18th (AIMT, ...Read the original story w/Photo

    Nov 18, 2016 | AmericanBankingNews.com

    The firm currently has a $40.00 price target on the stock, up from their previous price target of $38.00. had its outperform rating reiterated by analysts at Cowen and Company.

    Comment?

  11. CareDx Inc. (CDNA) Rating Increased to Buy at Zacks Investment ResearchRead the original story w/Photo

    Nov 18, 2016 | AmericanBankingNews.com

    The firm presently has a $3.75 price target on the stock. Zacks Investment Research's price objective indicates a potential upside of 19.05% from the stock's previous close.

    Comment?

  12. CareDx Inc. (CDNA) Upgraded to Buy at Zacks Investment ResearchRead the original story w/Photo

    Nov 18, 2016 | AmericanBankingNews.com

    The firm currently has a $3.75 price objective on the stock. Zacks Investment Research's target price suggests a potential upside of 19.05% from the stock's previous close.

    Comment?

  13. Atara Biotherapeutics Inc. (ATRA) Rating Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Oct 26, 2016 | AmericanBankingNews.com

    According to Zacks, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.

    Comment?

  14. Investment Analysts' Upgrades for October, 25th (ABY, AIMT, ALDX,...Read the original story w/Photo

    Oct 25, 2016 | AmericanBankingNews.com

    According to Zacks, "Atlantica Yield Plc owns, manages and acquires a diversified portfolio of contracted assets in the power and environment sectors. It operates primarily in North America, South America and Europe.

    Comment?

  15. Aimmune Therapeutics Inc. (AIMT) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    Oct 25, 2016 | AmericanBankingNews.com

    According to Zacks, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage.

    Comment?

  16. CareDx Inc. (CDNA) Upgraded to Hold by Zacks Investment ResearchRead the original story w/Photo

    Oct 11, 2016 | AmericanBankingNews.com

    According to Zacks, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients.

    Comment?

  17. Atara Biotherapeutics Inc. (ATRA) Upgraded to Hold by Zacks Investment ResearchRead the original story w/Photo

    Oct 10, 2016 | AmericanBankingNews.com

    According to Zacks, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.

    Comment?

  18. Investment Analysts' Updated EPS Estimates for October, 10th (AA,...Read the original story w/Photo

    Oct 10, 2016 | AmericanBankingNews.com

    They currently have a $30.00 price target on the stock. was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating.

    Comment?

  19. Research Analysts' Recent Ratings Changes for Aimmune TherapeuticsRead the original story w/Photo

    Oct 10, 2016 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Aimmune Therapeutics in the last few weeks: 9/26/2016 - Aimmune Therapeutics is now covered by analysts at JMP Securities. They set an "outperform" rating and a $30.00 price target on the stock.

    Comment?

  20. Aimmune Therapeutics (AIMT) - Analysts' Recent Ratings UpdatesRead the original story w/Photo

    Sep 29, 2016 | AmericanBankingNews.com

    They set an "outperform" rating and a $30.00 price target on the stock. 9/23/2016 - Aimmune Therapeutics had its "overweight" rating reaffirmed by analysts at Piper Jaffray Cos..

    Comment?

Brisbane Job Listings
View or post Brisbane job listings on Topix.
Brisbane Real Estate
News, listings, and foreclosures in Brisbane from Topix.
Brisbane Mortgages
Find mortgage rates in Brisbane on Topix.